#alk

PODCAST POCA FIDUCIA NELLA SANITA’ PUBBLICA IN ITALIA, NEUROBLASTOMA E CAR-T, CAMBIA IL CLIMA IN TICINO

35 - Rimborsabilità di lorlatinib in prima linea nel NSCLC ALK riarrangiato

Un Estudio de Caso y la Importancia de las Pruebas NGS en la Enfermedad ALK y ROS1

S7 E30 "Cultivate lasting confidence"

#139 DER GROßE KORNTEST

Circulating Tumor DNA in NSCLC

Spring is here and it's time to buy, plant and trim

Targeted Therapies Forum, Episode 8: Detecting TKI Resistance with Liquid Biopsy

Episode 20 - May Voting

Episode 18 - Lost Without You

Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?

Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue

Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)

Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"

Dr. Ravi Salgia: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?

Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?

Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?

Dr. Sarah Goldberg on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"

Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing

Dr. Rosalyn Juergens on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"

Dr. David Spigel: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"

Dr. Greg Riely: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (video)

Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Dr. Rosalyn Juergens on Managing Acquired Resistance to Targeted Therapies for Advanced NSCLC

GRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology,

What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?

Dr. Heather Wakelee on "Which molecular marker tests do you seek?"

Dr. Ravi Salgia on "Which patients do you send molecular marker testing for, and what tests do you seek?"

Squamous Lung Cancer, Part 2: Genomic Testing (video)

Dr. Geoffrey Oxnard on What Molecular Markers to Test for in Advanced NSCLC, and in Whom?

Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

Dr. David Spigel on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Dr. Karen Kelly: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

Dr. Ravi Salgia: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

Dr. Phil Bonomi, How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?

ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (video)

Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

Dr. Phil Bonomi: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

ALK Positive Lung Cancer Forum 2014: Next Generation ALK Inhibitors

Dr. David Spigel on "Which molecular marker tests do you seek?"

Dr. Greg Riely on "Which patients do you send molecular marker testing for, and what tests do you seek?"

Squamous Lung Cancer, Part 2: Genomic Testing (audio)

Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

ALK Positive Lung Cancer Forum 2014: Testing for ALK

ALK Positive Lung Cancer Forum 2014: Xalkori